SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 200.79-0.2%Nov 14 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dwc who wrote (20597)5/12/1998 5:18:00 PM
From: Henry Niman  Read Replies (1) of 32384
 
Here's their take on upcoming events:

UPCOMING EVENTS: Upcoming events for Ligand include: (1) Initiation of Phase II trial of
Targretin in breast cancer expected in Q2:98; (2) Results of Targretin in Phase II/III to treat lung cancer
and Phase I/II in combination with interferon to treat lung cancer expected in 2H:98; (3) File Topical
Panretin to treat KS expected in Q2:98 with approval expected by early 1999; (4) File oral Panretin to
treat KS expected in 1999; (5) Ontak in front of Oncologic Drugs Advisory Committee on June 1-2,
1998; (6) Additional oral Panretin data to treat KS expected at ASCO; (7) Full presentation of the
international and North American Phase III topical Panretin data at the International AIDS Conference
in Geneva in late June/early July; (8) Filing of multiple INDs by Ligand and the company's partners.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News